Alnylam Pharmaceuticals Inc. (ALNY) Financial Ratios & Valuation Metrics Analysis - P/E, ROE, Debt Ratios & Profitability - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Alnylam Pharmaceuticals I...

    NASDAQ: ALNY · Real-Time Price · USD
    452.00
    -1.54 (-0.34%)
    At close: Sep 05, 2025, 3:59 PM
    454.00
    0.44%
    Pre-market: Sep 08, 2025, 05:33 AM EDT

    Alnylam Pharmaceuticals Ratios and Metrics

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    PE Ratio
    		 -107.99 -54.31 -25.57 -23.55
    PEG Ratio
    		 2.79 0.87 -0.88 6.76
    PS Ratio
    		 13.36 13.08 27.88 23.79
    PB Ratio
    		 447.73 -108.36 -182.78 34.15
    P/FCF Ratio
    		 -705.29 569.99 -47.15 -27.97
    P/OCF Ratio
    		 -3.61K 229.54 -53.43 -31.3
    OCF/S Ratio
    		 -0.00 0.06 -0.52 -0.76
    Debt / Equity Ratio
    		 19.32 -5.92 -8.34 1.70
    Quick Ratio
    		 2.71 2.99 3.34 3.91
    Current Ratio
    		 2.78 3.08 3.51 4.04
    Asset Turnover
    		 0.53 0.48 0.29 0.23
    Interest Coverage
    		 -1.25 -2.33 -5.03 -4.95
    Return on Equity
    		 -4.15 2.00 7.15 -1.45
    Return on Assets
    		 -0.07 -0.11 -0.32 -0.23
    Return on Invested Capital
    		 -0.04 -0.1 -0.28 -0.24
    Dividend Yield
    		 n/a n/a n/a n/a
    Payout Ratio
    		 n/a n/a n/a n/a
    Gross Profit Margin
    		 0.86 0.83 0.84 0.83
    Net Profit Margin
    		 -0.12 -0.24 -1.09 -1.01
    Pretax Profit Margin
    		 -0.17 -0.24 -1.09 -1.01
    Operating Profit Margin
    		 -0.08 -0.15 -0.76 -0.84
    FCF Margin
    		 -0.02 0.02 -0.59 -0.85
    EBITDA Margin
    		 -0.08 -0.14 -0.89 -0.78

    Add to Watchlist